论文部分内容阅读
目的观察伊曲康唑治疗血液系统恶性肿瘤患者伴发真菌感染的效果。方法选择我院2004年2月至2009年6月收治的恶性血液病合并侵袭性真菌感染患者(IFI)31例并分为两组,A组17例,予伊曲康唑注射液静脉注射2 d后改口服液续贯治疗,B组14例,予伊曲康唑注射液静脉注射14 d后改口服液续贯治疗。结果A组与B组IFI患者有效率分别为64.7%和64.3%。结论恶性血液病合并侵袭性真菌感染者应用改良伊曲康唑方案治疗有效,节约了医疗费用,其抗感染疗效与免疫力恢复速度密切相关。
Objective To observe the efficacy of itraconazole in the treatment of hematological malignancies with fungal infection. Methods Thirty-one patients with malignant hemorrhagic disease complicated with invasive fungal infection (IFI) who were admitted to our hospital from February 2004 to June 2009 were divided into two groups. Group A (n = 17) received intravenous injection of itraconazole 2 d after oral liquid continued treatment, B group 14 cases, intravenous injection of itraconazole 14 d after oral fluid replacement therapy. Results The effective rates of IFI patients in group A and group B were 64.7% and 64.3% respectively. Conclusions The treatment of patients with invasive hematologic malignancies with modified fungal infection is effective in the treatment of itraconazole, saving the medical expenses. The anti-infective efficacy is closely related to the speed of immune recovery.